This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months.
Impressive long-term response with pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastasis / Russillo, M.; Ferretti, G.; Vidiri, A.; Gasparro, S.; Cognetti, F.; Pellegrini, D.; Fabi, A.. - In: IN VIVO. - ISSN 0258-851X. - 32:4(2018), pp. 839-842. [10.21873/invivo.11317]
Impressive long-term response with pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastasis
Russillo M.;Cognetti F.;
2018
Abstract
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months.File | Dimensione | Formato | |
---|---|---|---|
Russillo_Impressive_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
164.9 kB
Formato
Adobe PDF
|
164.9 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.